Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

612
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
612
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

2.0K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.0K
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.9K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.9K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

141
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
141
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

99
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
99
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

3.4K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temporal Patterns of Allergen Sensitisation in the General Population: The LEAD Study.

Clinical and translational allergy·2026
Same author

Physiological characteristics and temporal transitions of preserved ratio impaired spirometry.

ERJ open research·2026
Same author

Breathing and speech patterns for predictive modelling of exacerbations of asthma and COPD.

Respiratory medicine·2026
Same author

Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.

Seminars in respiratory and critical care medicine·2026
Same author

Predicting severe COPD exacerbations: are we ready for risk-based care?

Thorax·2026
Same author

Prevalence of Type 2 Inflammation in Chronic Obstructive Pulmonary Disease Patients With Frequent Exacerbations.

Allergy·2026

Related Experiment Video

Updated: Dec 13, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.2K

Decreased Risk of COPD Exacerbations in Obese Patients.

Lian Smulders1, Anniek van der Aalst1, Erik D E T Neuhaus1

  • 1Department of Pulmonary Medicine, Zuyderland Medical Center, Heerlen, The Netherlands.

COPD
|August 6, 2020
PubMed
Summary

Obese patients hospitalized with chronic obstructive pulmonary disease (COPD) exacerbations experience fewer exacerbations and longer readmission times. This obesity paradox suggests higher BMI may improve COPD outcomes.

Keywords:
COPDhospitalizationobesityoverweightsurvival

More Related Videos

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.4K

Related Experiment Videos

Last Updated: Dec 13, 2025

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
07:10

Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease

Published on: August 24, 2019

10.2K
Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
04:03

Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD

Published on: September 27, 2024

1.2K
Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.4K

Area of Science:

  • Pulmonary Medicine
  • Metabolic Disorders
  • Clinical Epidemiology

Background:

  • Obesity paradox: enhanced survival in obese patients with chronic obstructive pulmonary disease (COPD).
  • Mechanisms underlying the obesity paradox in COPD remain unclear.
  • COPD exacerbations significantly impact patient survival.

Purpose of the Study:

  • To investigate the relationship between Body Mass Index (BMI) classes and COPD exacerbation frequency.
  • To analyze the time to readmission and survival rates in hospitalized COPD patients across different BMI categories.
  • To explore the 'obesity paradox' in the context of COPD exacerbations.

Main Methods:

  • Stratification of 604 hospitalized COPD patients into BMI groups (<18.5, 25, 30, ≥35 kg/m²).
  • Five-year follow-up to assess exacerbation frequency, time to readmission, and survival.
  • Regression analysis to identify associations between BMI and clinical outcomes, controlling for confounders.

Main Results:

  • Obese patients exhibited a 34-40% decrease in 5-year exacerbation frequency compared to normal-weight patients.
  • Moderately obese patients had up to 1.7 times longer time to readmission (954 days) versus normal-weight patients (564 days).
  • Regression analysis confirmed BMI was independently associated with improved time to readmission and survival.

Conclusions:

  • A 'dose-dependent' reduction in exacerbation frequency was observed with increasing BMI in COPD patients.
  • Increased BMI is associated with a longer time to readmission following hospitalization for COPD exacerbation.
  • Findings support the obesity paradox, indicating potential survival benefits for obese individuals with COPD.